7-117590377-G-T
Variant summary
Our verdict is Likely pathogenic. Variant got 8 ACMG points: 8P and 0B. PM1PM2PP3_Strong
The NM_000492.4(CFTR):c.1704G>T(p.Leu568Phe) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000758 in 1,451,032 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_000492.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 8 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CFTR | NM_000492.4 | c.1704G>T | p.Leu568Phe | missense_variant | Exon 13 of 27 | ENST00000003084.11 | NP_000483.3 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 0.00000758 AC: 11AN: 1451032Hom.: 0 Cov.: 30 AF XY: 0.00000554 AC XY: 4AN XY: 721718
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Cystic fibrosis Uncertain:3Other:1
- -
- -
The p.L568F variant (also known as c.1704G>T), located in coding exon 13 of the CFTR gene, results from a G to T substitution at nucleotide position 1704. The leucine at codon 568 is replaced by phenylalanine, an amino acid with highly similar properties. This variant was observed in individuals diagnosed with congenital bilateral absence of the vas deferens (CBAVD) and/or idiopathic chronic pancreatitis; however, complete genotype information was not provided (Dörk T et al. Hum. Genet., 1997 Sep;100:365-77; Audrezet MP et al. J Mol Diagn, 2008 Sep;10:424-34; Amato F et al. J Mol Diagn, 2012 Jan;14:81-9). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. -
This CFTR variant (rs397508275) has been observed in the heterozygous state in males with congenital absence of the vas deferens, but has not been identified in patients with classic cystic fibrosis to our knowledge. It is absent from two large population datasets and while it is present in ClinVar, no classification is provided. Leu568 is the first residue of the highly conserved Walker B ATP-binding motif in the first nucleotide binding domain of CFTR. This suggests that this substitution may be functionally signficant, however no functional studies have been performed to our knowledge. Of three bioinformatics tools queried, two predict that this substitution would probably be damaging and the third predicts that it would be tolerated. The leucine at this position is highly evolutionarily conserved among the species assessed. Due to the lack of functional data, we consider the clinical significance of c.1704G>T to be uncertain at this time. -
not specified Uncertain:1
Variant summary: CFTR c.1704G>T (p.Leu568Phe) results in a non-conservative amino acid change located in the ABC transporter-like, ATP-binding domain (IPR003439) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 250456 control chromosomes in gnomAD. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.1704G>T has been reported in the literature in individuals affected with Cystic Fibrosis or other CFTR-related diseases, however in most cases, strong evidence for causality could not be found (example: Amato_2012, Erdogan_2021, Liechti-Gallati_1999, Audrezet_2008, Masson_2013, Bozdogan_2021). In one Turkish individual affected with congenital absence of the vas deferens, c.1704G>T was at a compound heterozygous state along with a second pathogenic variant in CFTR (example: Dork_1997). These data do not allow any conclusion about variant significance. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 22020151, 18687795, 33572515, 9272157, 34860163, 10439967, 23951356). Three submitters have cited clinical-significance assessments for this variant to ClinVar after 2014 (all VUS). Based on the evidence outlined above, the variant was classified as uncertain significance. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at